These findings are consistent with other studies that suggest that effective CD8+ T-cell responses can be induced in PDAC through combination therapies, despite the inherent resistance of this tumor type to single-agent immunotherapies 38, 39. The gene discussed is CD8A; the disease is neoplasm.